×
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT

Acumen's Alzheimer's drug passes initial safety test

In the Acumen trial, 10.4% of treated participants (5 people) developed a brain swelling condition known as ARIA-E associated with amyloid-targeting treatments.
Last Updated : 16 July 2023, 08:07 IST

Follow Us :

Comments
ADVERTISEMENT
Published 16 July 2023, 08:07 IST

Follow us on :

Follow Us